Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Hope we close above $50 this week!! Then 40s will be History for good!!
$$IONS$$
That sure helps Percival: In time i hope we will be well enough financed to advance drugs alone.
But with our big pipeline, we need them now.
Of course, with the "huge benefits" they take a huge bite of the proceeds.
Shrub!! However, the important thing is,,, right now IONS has more recognition by major Pharmaceutical Giants than never before!!
That comes with huge benefits!!
$$IONS$$
Percival; you are assuming that all our clinical trials are successful, which is unlikely. New drug development has an inherently high failure rate, and that should be expected by a reasonable share holder.
Expect the PPS to fluctuate all over the place along the way.
That said, IONS is one of my larger holdings.
Folks this is a +$200 Stock,,,,,
If possible I may load all my entire Portfolio in $IONS$.
The $65 price target is a joke,,,,this stock nust have a Price Target of +$300 !!
6:23 am ET
*Ionis Pharmaceuticals +5.8% Premarket @$49.85; Co Announced Licensing Deal With Novartis
Benzinga
5:47 am ET
Novartis to Pay Up to $1.6 Bln to Ionis, Unit for Rights to Two Cardiovascular Drugs
Dow Jones
4:32 am ET
*UPDATE: Ionis, Akcea are Eligible to Receive $225M in Near-term Payments, Including Immediate $75M Up-front Option Payment, $100M Equity Investment Which Equates to 1,631,435 Shares at $61.30/Share
Benzinga
4:25 am ET
Ionis, Akcea Enter into Strategic Collaboration with Novartis Develop and Commercialize AKCEA-APO(a)-L Rx and AKCEA-APOCIII-L Rx
$$$$IONS$$$
It's not a potential block-buster;
but it's solid validation.
We'll probably need something bigger to see a major SP rise.
FDA Approval
Now we should see something.
Why worry, they are parasites with short lives.
We get to take their $ when we get a major FDA approval.
A Pending Short Squeeze in the Works with $$IONS$$.
This may easily run to 60s then to 70s!!
http://www.shortanalytics.com/getshortchart.php?tsymbol=ions
IONS short-interest Chart !! vs Longs!!
http://www.shortanalytics.com/getshortchart.php?tsymbol=ions
$$IONS$$
Hope we move multiple Dollars in the next few days before years end!!
$$IONS$$
The Short interest is amazingly high here!!
We need to Squeeze them all the way to 70s!!
Im long and trust $$IONS$$!!
I bought in years ago and have done quite nicely...The pipeline is amazing.
I sure see it as continuing to rise and feel dumb for having sold some off for a profit.
I bought in years ago and have done quite nicely...The pipeline is amazing.
I sure see it as continuing to rise and feel dumb for having sold some off for a profit.
Broke $50 this AM
It is there to stay. Wish I had some $22. stock
$ 22 was my average buy in price over several purchases and 9 years.
But all this sort of discourse is of no real use and clutters up the boards.
"Calm down"? Notice the number of !! in your response? Tsk.
What!!,,,,
The Fragile Ego is,actually on yr End !!
You think buying ISIS at 22 was a great buy to post on the message board!!! Ego boaster !!!!,,,,(To begin With) I never posted my buying price to boast and boost my ego like you.
But Now I'm LETTING YOU KNOW THAT CRAMER HAD THE CEO CNBC IN 2011 AND I BOUGHT ISIS AT LESS THAN 8 DOLLARS ALL THE WAY TO THE 70s Price!!. (Yes the PRICE WAS AT 70.00-(SEVENTY)- BEFORE IT FELL AND YOU BOUGHT)--I sold for greater profits than yr ego may or can ever Imagine.
I have been in and out of isis/ions for lots of profits, and lots of times.
You thought yr ego was boosted by talking about buying prices.
Well,,, Calm down!! ,,,others have bought lower and made more profits than you ego thought.
IONS
i bought IONS ( then ISIS) at $22.
It's now $41.46
And most of the potential rise remains untapped.
The pipeline is just juicy.
Say Percy, why do you find it necessary to attack other folks
rather than put up meaningful arguments?
It really adds nothing to anything but your fragile ego.
and wastes all our time.
Look at the Price of IONS ,,,,,Stupid is as Stupid does/is!!!
However, my laughter has come last.!! ROFLMAO!!! 39s and printing!!
Up on trump hump and good trial news.
Sold 1/3 interest at 29% rise.
Will buy back later when it settles back down.
Pipeline too juicy not to get back in.
I don't usually trade, but this was hard to pass.
Who exactly is laughing now??
Ignorance is the saddest lack of brains!!!
$IONS$ 37s and printing!!!
Looking $olid!!!!!
IONS is a great $$$$$ opportunity.
Keeping laughing! > HUGE NEWS OUT: Biogen, Ionis shares rally on positive trial of treatment for spinal muscular atrophy
13 minutes ago - DJNF
Shares of Biogen Inc. and Ionis Pharmaceuticals Inc. (IONS) rallied premarket after the companies reported positive results from a late-stage trial of an investigational treatment for later-onset spinal muscular atrophy. The companies said the trial met its primary endpoint at the interim analysis of Cherish, a study evaluating Spinraza, or nusinersen. The analysis "found that children receiving Spinraza experienced a highly statistically significant improvement in motor function compared to those who did not receive treatment," the companies said in a statement. Biogen is preparing for the launch of the treatment in the U.S., possibly as early as year-end or the first quarter of 2017. Biogen shares rose 3.5% in premarket trade, while Ionis was up 12.5%. S&P 500 futures were up 1.4%.
-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com
(END) Dow Jones Newswires
November 07, 2016 08:44 ET (13:44 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
$35 is proving to be a Strong Support Level!!
Totally agree.
$IONS$
looking at the pipeline, i have to think you are understating.
This is a stock to add to on the dips nd forget about for a few years.
Psssst...the iphone 7 was sold out shortly after it was released.
Hope you aren't betting real money.
There are quite a number of players big enough to manipulate the short term PPS. Almost impossible to tell which one, if any ,is responsible.
We are compulsively pattern seeking animals and tend to impose our wishes and perceptions on reality.
As a LTBH guy, i don't much care about most of the short term flux. Small day traders generally lose $ playing against the big guys.
MMs don't want to Run the Stock yet, they are trying to avoid ""News Day-traders"",,,yet at the same time letting their real friends load//accumulate quietly at these low prices!!
This will Run soon!!
$$IONS$$
Seeing as the SP hardly budged on the news i'm wondering; why?
It's further confirmation of the validity of our platform and a promise of future cash flow.
The run down infers it could be used to treat a pretty large % of the population with similar maladies..and that'd be big bucks!
How could that be worth a rise of only .29%?
Thanks Percival: That's excellent news.
Any idea how big that market is?
Out-standing News is Out in IONS!!
https://finance.yahoo.com/news/akcea-announces-publication-lancet-clinical-110000886.html
The Sky is the limit here!!
$$IONS$$
Do you like penny Stocks! Check out $SFOR$,,Potential life Changer.
Company is for real!! No DEBT and Have Money in the Bank,,,Winning Law Siuts!!
I've been long for quite a while and think $46 will be left far behind in the next few years.
Note that the analysts are generally about as accurate as random chance.
We are headed to $46 Again,,,Are you still Holding??
Let no one be left behind!!,,Analysts have already raised the Target Price to $46!!
$IONS$
Analysts have already raised the Target Price to $46!!
We are going to $46,,,,IONS is one of the leaders in their Health Care Field!! Hedge Funds are scooping up $35 Calls,,,but Analysts have already raised the Target Price to $46!!
$IONS$
Great call SW. What else are you holding? I agree with you about AAPL btw, dead money until they come up with something new. Only so many times they can shrink and enlarge iPhones and iPads and get away with calling it innovation.
This one was pretty obvious on the 11,000 Oct $32 calls that were bought. Follow the money. You talk about insider information.
Well finally! ..Up 35% on clinical trial news and i think this may be our first antisense drug to make it over the line...Root!
This oughta wake they board up.
Looking strong and holding up nice today. Grabbing Sept 16th $30 calls. GL longs!
We are the leading company in RNA-targeted drug discovery and development with a pipeline of first-in-class or best-in-class medicines with the potential to provide high value for patients with significant unmet medical needs. We have created an efficient and broadly applicable drug discovery platform. Using this platform, we believe that we are revolutionizing medicine with the goal to improve the quality of, and save, lives.
We have discovered and are developing three potentially transformational drugs, nusinersen, IONIS-TTRRx and volanesorsen, which we believe are close to commercialization. We designed each of these three drugs to treat patients with orphan diseases who have limited or no therapeutic options. In total, we are developing these three drugs for six different patient populations. In 2015, we completed target enrollment in the first pivotal Phase 3 study for each of these three drugs, and we anticipate reporting data from these studies in the first half of 2017. We designed nusinersen to treat patients with spinal muscular atrophy, or SMA, a severe motor-neuron disease that is the leading genetic cause of infant mortality. We designed IONIS-TTR Rx to treat patients with transthyretin amyloidosis, or TTR amyloidosis, a fatal disease in which patients experience progressive buildup of amyloid plaque deposits in tissues throughout the body, including peripheral nerves, heart, intestinal tract, kidney and bladder. We designed volanesorsen to treat patients with diseases associated with extremely high levels of triglycerides, including patients with two severe and rare genetic conditions called familial chylomicronemia syndrome, or FCS, and patients with familial partial lipodystrophy, or FPL. We anticipate that the data from our pivotal Phase 3 studies of these drugs, if positive, will support global regulatory filings for each drug. We believe that the significant unmet medical need and the severity of these diseases could warrant a rapid path to market. Already our partners for these programs, Biogen for nusinersen and GSK for IONIS-TTR Rx , are preparing to commercialize these drugs. Our wholly owned subsidiary, Akcea Therapeutics Inc., or Akcea, is preparing to commercialize volanesorsen. All three companies are engaging in pre-commercialization activities to understand the patient journey, build disease awareness with physicians and patients and develop their launch plans. We believe all three of these drugs have the potential to reach the market in the next several years.
To maximize the value of volanesorsen and other earlier-stage drugs for serious cardiometabolic disorders, we formed Akcea Therapeutics to focus on developing and commercializing these drugs. Akcea’s pipeline includes volanesorsen, IONIS-APOCIII-L Rx , IONIS-APO(a)-L Rx and IONIS-ANGPTL3-L Rx . Moving these drugs into a company that we own and control allows us to retain substantial value from them and ensures Ionis’ core focus remains on innovation. Akcea is building development and commercialization expertise in lipid and cardiometabolic diseases, including highly trained, specialized medical, marketing and sales teams, to successfully commercialize volanesorsen and the other lipid drugs in its pipeline. To learn more about Akcea Therapeutics, visit Akceatx.com.
Bought 2k today. Looks way too cheap....Paid 22....
I just hope the financial report on Feb 25th will have some,,""Awesome News""!!
$$IONS$$
Perceval,
The CEO was on Mad Money some time ago. Didn't seem like he had a grip on the questions Kramer was firing at him. That shouldn't matter but your right they a lot on the stove and the sp will move quick when they get there ducks in a row.
GLTA
This Stock with 38 drugs in pipeline.
Is way under-valued!!
Pathetic Price of $35!!
The Stock should be trading above $100!!
$$IONS$$
Followers
|
47
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
488
|
Created
|
02/21/06
|
Type
|
Free
|
Moderators |
Ionis Pharmaceuticals, Inc., through its drug discovery platform based on antisense technology, discovers and develops drugs that bind to RNA antisense technology. The company has commercialized its antisense drug and has 19 drugs in development. Ionis' drug development programs are focused on treating cardiovascular, metabolic, and severe neurodegenerative diseases and cancer. It licenses its drugs to partners prior to late-phase development and commercialization. The company and Alnylam Pharmaceuticals jointly own Regulus Therapeutics Inc., a company focused on the discovery, development, and commercialization of microRNA therapeutics. Ionis is the owner or exclusive licensee of approximately 1,600 issued patents worldwide. The company was founded in 1989 and is based in Carlsbad, California.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |